secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001193125-23-032729
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FLAG amends merger with Calidi; Continuation Shares to be issued at closing without price targets
--------------------------------------------------------------------------------

- Up to 2,000,000 Continuation Shares to be issued pro rata to non-redeeming FLAG public stockholders at closing.
- For every 100,000 shares not redeemed, FLAG issues 48,450 Continuation Shares, capped at 2M total.
- Amendment removes prior price-target condition; Continuation Shares now issued automatically at deal close.
- Amendment signed Feb 9, 2023; business combination with Calidi Biotherapeutics remains pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000119312523032729/0001193125-23-032729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000119312523032729/d442631d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-032729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer